Analog Devices, Inc. filed an 8-K press release on November 3, 2026, announcing the completion of its acquisition of Alif Semiconductor.
DaVita Inc. filed an 8-K on November 3, 2026, announcing that Chief Financial Officer Joel Ackerman and Group Vice President of Investor Relations Nic Eliason will participate in fireside chats at two upcoming investor conferences on November 9 and November 10, 2026.
Safehold Inc. (NYSE:SAFE) reported its third-quarter 2026 earnings results on November 3, 2026, disclosing revenue of $118.7 million and net income attributable to common shareholders of $28.8 million.
DG Capital Management, LLC, Dov Gertzulin, and DG Value Partners II Master Fund, LP filed a Schedule 13G with the SEC on November 3, 2026, disclosing beneficial ownership positions in Hydrofarm Holdings Group, Inc. common stock as of the triggering event date of October …
Sio Capital Management, LLC filed a Schedule 13G with the SEC on November 3, 2026, disclosing beneficial ownership of 500,000 Units of Rainier Acquisition Corporation as of September 30, 2026.
Chemung Financial Corporation filed a Form 8-K on November 3, 2026, disclosing under Regulation FD that management plans to participate in investor meetings during the fourth quarter of 2026 and has furnished a Third Quarter 2026 Investor Presentation as Exhibit 99.1.
SurgePays, Inc. filed a Form S-3 shelf registration statement with the SEC on November 3, 2026, seeking to register up to $100,000,000 in aggregate securities to replace its prior registration statement (File No. 333-273110).
Lite Strategy, Inc. filed a current report on Form 8-K on November 3, 2026, disclosing that Green Dragon Investments LLC exercised 517,509 Advisory Warrants in a cashless exercise on October 29, 2026, resulting in the issuance of 517,465 shares of common stock.
Reed's, Inc. filed a Form 8-K on November 3, 2026, disclosing a private placement of 17,421,602 shares of common stock to its majority stockholder, D&D Source of Life Holding, Ltd., at $0.574 per share for aggregate gross proceeds of approximately $10.0 million, with the …
Nurix Therapeutics, Inc. filed a current report on November 3, 2026, disclosing that collaboration partner Sanofi S.A. notified the company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program entirely.